Skeletal metastasis in renal cell carcinoma: Current and future management options

Cancer Treatment Reviews

Volumn 38, Issue 4, 2012, Pages 284-291

  Wood, Steven L ^a   Brown, Janet E ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bisphosphonates; Bone markers; Bone metastases; Denosumab; Renal cancer; Zoledronic acid

Indexed keywords

ACETIC ACID C 11; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ANGIOGENESIS INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; COLLAGEN TYPE 1; COLLAGENASE 3; DENOSUMAB; EPIDERMAL GROWTH FACTOR; FLUORODEOXYGLUCOSE F 18; IBANDRONIC ACID; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1DELTA; OSTEOPROTEGERIN; PAMIDRONIC ACID; PROSTAGLANDIN E2; SUNITINIB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BLADDER CANCER; BONE METABOLISM; BONE METASTASIS; BONE SCINTISCANNING; BONE TURNOVER; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER MODEL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; DNA MICROARRAY; FLU LIKE SYNDROME; FRACTURE; HUMAN; HYPERCALCEMIA; JAW OSTEONECROSIS; KIDNEY CARCINOMA; LUNG CANCER; MELANOMA; MYELOMA; NEPHROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOPEDIC SURGERY; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; REVIEW; SPINAL CORD COMPRESSION; THYROID CANCER;

BONE NEOPLASMS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859157132     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.06.011     Document Type: Review

References (83)

1. Ferlay JBF, Pisani P, Parkin DM. Cancer incidence, mortality and prevalence worldwide. " GLOBOCAN2002" IARC CancerBase No. 5 Version 2.0, 2000.
2. Woodward E., Jagdev S., McParland L., et al. Skeletal complications and survival in renal cancer patients with bone metastases. Bone 2011, 48:160-166.
3. National Cancer Institute, SEER Statistical Fact Sheets http://seer.cancer/gov.
4. Zekri J., Ahmed N., Coleman R.E., Hancock B.W. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 2001, 19:379-382.
5. Lipton A., Columbo-Berra A., Bukowski R.M., Rosen L., Zheng M., Urbanowitz G. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res 2004, 10:s6397-s6403.
6. Szendroi A., Dinya E., Kardos M., et al. Prognostic factors and survival of renal clear cell carcinoma patients with bone metastases. Pathol Oncol Res 2010, 16:29-38.
7. Tan T.H., Pranavan G., Haxhimolla H.Z., Yip D. New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies. Asia-Pacific J Clin Oncol 2010, 6:5-18.
8. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New Engl J Med 2007, 356:115-124.
9. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
10. Brown J.E., Coleman R.E. Metastatic bone disease. Developing strategies to optimise management. Am J Cancer 2003, 2:269-281.
11. Smith M.R. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rev 2005, 31(Suppl 3):19-25.
12. Yuasa T., Urakami S., Yamamoto S., et al. Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis. Clin Exp Metastasis. 2011, 28:405-411.
13. Kingsley L.A., Fournier P.G., Chirgwin J.M., Guise T.A. Molecular biology of bone metastasis. Mol Cancer Ther 2007, 6:2609-2617.
14. Mikami S., Katsube K., Oya M., et al. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinoma. J Pathol 2009, 218:530-539.
15. Roodman G.D. Mechanisms of bone metastasis. N Engl J Med 2004, 350:1655-1664.
16. Sohaib S.A., Cook G., Allen S.D., Eisen T., Gore M. Comparison of whole body MRI and bone scintigraphy in the detection of bone metastases in renal cancer. Brit J Radiol 2009, 82:632-639.
17. Kozlowski J.M. Management of distant solitary recurrence in the patient with renal cancer. Contralateral kidney and other sites. Urol Clin North Am 1994, 21:601-624.
18. Bouchlouche K., Oehr P. Recent developments in urologic oncology: positron emission tomography molecular imaging. Curr Opin Oncol 2008, 20:321-326.
19. Griffin N., Gore M.E., Sohaib S.A. Imaging in metastatic renal cell carcinoma. AJR 2007, 189:360-370.
20. Kotzerke J., Linné C., Meinhardt M., et al. [1-(11)C]acetate uptake is not increased in renal cell carcinoma. Eur J Nucl Med Mol Imaging 2007, 34:884-888.
21. Datta A., Panwar P., Chuttani K., Mishra A.K. Synthesis of 99mTc-DOTMP and its preclinical evaluation as a multidentate imaging agent for skeletal metastases. Cancer Biother Radiopharm 2009, 24:123-128.
22. Glaudemans AWJM, Lam MGEH, Veltman NC, Dierckx RAJO, Signore A. The contribution of nuclear medicine in the diagnosis of bone metastases. In: Kardamakis D, Vassiliou V, Chow E, editors. Bone metastases: a translational and clinical approach. Springer; 2009. p. 137-61.
23. Solomou E, Kazanti A, Romanos O, Kardamaki D. Magnetic resonance imaging of metastatic bone disease. In: Kardamakis D, Vassilou V, Chow E, editors. Bone metastases: a translational and clinical approach. Springer; 2009. p. 163-81.
24. Saad F. New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Cancer Treat Rev 2008, 34:183-192.
25. Coleman R.E. Risks and benefits of bisphosphonates. Br J Cancer 2008, 98:1736-1740.
26. Costa L., Major P. Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Prac Oncol 2009, 6:163-174.
27. Rosen L.S., Gordon D., Tchekmedyain N.S., et al. Long term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non small cell lung carcinoma and other solid tumours. Cancer 2004, 100:2613-2620.
28. Kohno N., Aogi K., Minami H., et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. J Clin Oncol 2005, 23:3314-3321.
29. Rosen L.S., Gordon D., Kaminski M., et al. Long term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer 2003, 98:1735-1743.
30. Saad F., Gleason D.M., Murray R., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone refractory prostate cancer. J Natl Cancer Inst 2004, 96:879-882.
31. Lipton A., Zheng M., Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003, 98:962-969.
32. Christodoulou C., Pervena A., Klouvas G., et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009, 76:209-211.
33. Ayllon J., Vacher-Launay V., Medioni J., Cros C., Spano J.P., Oudard S. Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?. Ann Oncol 2009, 20:600-601.
34. Brunello A., Saia G., Bedogni A., Scaglioni D., Basso U. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone 2009, 44:173-175.
35. Hasegawa Y., Mita K., Matsubara A. Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosupressed renal transplant recipient. Int J Clin Oncol 2009, 14:465-467.
36. Weitzman R., Sauter N., Eriksen E.F., et al. Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Critical Rev in Oncol/Haematol 2007, 62:148-152.
37. Lipton A., Jun S. RANKL inhibition in the treatment of bone metastasis. Curr Opin Support Palliat Care 2008, 2:197-203.
38. Henry DH, Costa L, Goldwasser FJ, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; [Epub ahead of print].
39. Van den Wyngaert T, Wouters K, Huizing MT, Vermorken JB. RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ). Support Care Cancer 2011; [Epub ahead of print].
40. Brown J.E., Barrios C.H., Diel I.J., et al. Incidence, outcomes of osteonecrosis of the jaw from an integrated analysis of the pivotal randomized double-blind, double-dummy phase 3 trials comparing denosumab, zoledronic acid for treatment of bone metastases in advanced cancer patients or myeloma. Bone 2011, 48:27.
41. zolnierek J., Nurzyński P., Langiewicz P., et al. Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. J. Cancer Res Clin Oncol 2009, 136:371-378.
42. Paule B., Brion N. Efficacy of sunitinib in patients with renal cell carcinoma with bone metastases. Anticancer Res 2010, 30:5165-5168.
43. Fottner A., Szalantzy M., Wirthmann L., et al. Bone metastases from renal cell carcinoma: patient survival after surgical treatment. BMC Musculoskeletal Disorders 2010, 11:145-151.
44. Leer JWH, van-der-Linden YM. Radiotherapy and bone metastases. In: Kardamakis D, Vassilou V, Chow E, editors. Bone metastases: a translational and clinical approach. Springer; 2009. p. 185-93.
45. Halperin E.C., Harisiadis L. The role of radiation therapy in the management of metastatic renal cell carcinoma. Cancer 1983, 51:614-617.
46. Reichel L.M., Pohar S., Heiner J. Buzaianu-EM, Damron-TA. Radiotherapy to bone has utility in multifocal metastatic renal carcinoma. Clin Orthop Relat Res 2007, 459:133-138.
47. Rades D., Walz J., Stalpers L.J.A. Short-course radiotherapy (RT) for metastatic spinal cord compression (MSCC) due to renal cell carcinoma: Results of a retrospective multi-center study. European Urol 2006, 49:846-852.
48. Kijima T., Fuji Y., Okubo Y., et al. Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate. BJU Int 2008, 103:620-624.
49. Sciarra A., Gomez A.M., Gentilucci A., et al. Adjuvant therapy with sorafenib in bone-metastases bilateral renal carcinoma: a case report. Eur Urol 2007, 52:597-599.
50. Weber K.L., Pathak S., Multani A.S., Price J.E. Characterization of a renal cell carcinoma cell line derived from a human bone metastasis and establishment of an experimental nude mouse model. J Urol 2002, 168:774-779.
51. Weber K.L., Doucet M., Price J.E., Baker C., Kim S.J., Fidler I.J. Blockade of epidermal growth factor receptor signalling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res 2003, 63:2940-2947.
52. Strube A., Stepina E., Mumberg D., Schulz A., Hauff P., Käkönen S.M. Characterization of a new renal cell carcinoma bone metastasis mouse model. Clin Exp Metast 2010, 27:319-330.
53. Coleman R., Brown J., Terpos E., et al. Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directions. Cancer Treat Rev 2008, 34:629-639.
54. Fohr B., Dunstan C.R., Seibel M.J. Markers of bone remodelling in metastatic bone disease. J Clin Endocrinol Metab 2003, 88:5059-5075.
55. Kominsky S.L., Doucet M., Thorpe M., Weber K.L. MMP-13 is over-expressed in renal cell carcinoma bone metastasis and is induced by TGF-β1. Clin Exp Metast 2008, 25:865-870.
56. Lacey D.L., Timms E., Tan H.L., et al. Osteoprotogerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
57. Brown J.E., Cook R.J., Major P., et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumours. J Natl Cancer Inst 2005, 97:59-69.
58. Brown J.E., Lipton A., Cook R.J., Michaelson D., Coleman R.E., Saad F. Correlation of N-telopeptide of type I collagen (NTX) with survival and fractures in patients with bone metastases from renal cell carcinoma. J Clin Oncol 2009, 27(Suppl 15):e16016. (Abstract).
59. Klepzig M., Sauer-Eppel H. Jonas-D, Oremek GM. Value of procollagen type 1 amino-terminal propeptide in patients with renal cell carcinoma. Anticancer Res 2008, 28(4C):2443-2446.
60. Jung S.T., Ghert A., Harrelson J.M., Scully S.P. Treatment of osseous metastases in patients with renal cell carcinoma. Clin Orthop Relat Res 2003, 409:223-231.
61. Martin M., González-Palacios F., Cortés J., de la Haba J., Schneider J. Prognostic and predictive factors and genetic analysis of early breast cancer. Clin Trans Oncol 2009, 11:634-642.
62. Bohn O.L. Nasir, Brufsky A, et al. Biomarker profile in breast carcinomas presenting with bone metastasis. Int J Clin Exp Pathol 2010, 3:139-146.
63. Crispen P.L., Boorjan S.A., Lohse C.M., Leibovich B.C., Kwon E.D. Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer 2008, 113:450-460.
64. Kapoor A., Gharajeh A., Sheikh A., Pinthus J. Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma. Curr Oncol 2009, 16(Suppl 1):S60-S66.
65. Uhlman D.L., Nguyen P., Manivel J.C., et al. Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behaviour and prognosis. Clin Cancer Res 1995, 1:913-920.
66. Badalian G., Derecskei K., Szendroi A., Szendroi M., Timár J. EGFR and VEGFR2 protein expressions in bone metastases of clear cell renal cancer. Anticancer Res 2007, 27:889-894.
67. Ramankulov A., Lein M., Kristiansen G., Meyer H.A., Loening S.A., Jung K. Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. J Cancer Res Clin Oncol 2007, 133:643-652.
68. Kominsky S.L., Abdelmagid M., Doucet M., Brady K., Weber K.L. Macrophage inflammatory protein-1δ: A novel osteoclast stimulating factor secreted by renal cell carcinoma bone metastasis. Cancer Res 2008, 68:1261-1266.
69. Tan X., Zhai Y., Chang W., et al. Global analysis of metastasis-associated gene expression in primary cultures from clinical specimens of clear-cell renal-cell carcinoma. Int J Cancer 2008, 123:1080-1088.
70. Paule B., Deslandes E., LeMouel S.P., et al. Identification of a novel biomarker signature associated with risk for bone metastasis in patients with renal cell carcinoma. Int J Biol Markers 2010, 25:112-115.
71. Gregory P.A., Bracken C.P., Bert A.G., Goodall G.J. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 2008, 20:3112-3118.
72. Burk U., Schubert J., Wellner U., et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Reports 2008, 9:582-589.
73. Slaby O., Jancovicova J., Lakomy R., et al. Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J Exp Clin Cancer Res 2010, 29:90.
74. Bhattacharyya S., Byrum S., Siegel E.R., Suva L.J. Proteomic analysis of bone cancer: a review of current and future developments. Expert Rev Proteomics. 2007, 4:371-378.
75. Bhattacharyya S., Epstein J., Suva L.J. Biomarkers that discriminate multiple myeloma patients with or without skeletal involvement detected using SELDI-TOF mass spectrometry and statistical and machine learning tools. Disease Markers 2006, 22:245-255.
76. Li Y., Dang T.A., Shen J., et al. Plasma proteomics predicts chemotherapy response in osteosarcoma patients. Oncol Reports 2011, 25:303-314.
77. Allory Y., Matsuoka Y., Bazille C., Christiensen E.I., Ronco P., Debiec H. The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas. Clin Cancer Res 2005, 11:1190-1197.
78. Jiang Z., Chu P.G., Woda B.A., et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 2006, 7:556-564.
79. Ramnkulov A., Lein M., Johannsen M., et al. Serum Amyloid A as an indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. Cancer Lett 2008, 269:85-92.
80. Thompson R.H., Zang X., Lohse C.M., et al. Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res 2008, 68:6054-6058.
81. Ozcan A., Zhai Q., Javed R., et al. PAX-2 is a helpful marker for diagnosing metastatic renal cell carcinoma: comparison with the renal cell carcinoma marker antigen and kidney-specific cadherin. Arch Pathol Lab Med 2010, 134:1121-1129.
82. Zhao F., Guo W. Expression of stromal-derived factor-1 (SDF-1) and chemokine receptor (CXCR4) in bone metastasis of renal carcinoma. Mol Biol Rep 2010, 38:1039-1045.
83. Langbein S., Frederiks W.M., zur Hausen A.Z., et al. Metastasis is promoted by a bioenergetic switch: New targets for progressive renal cell cancer. Int J Cancer 2008, 122:2422-2428.